When is mounjaro going generic?

When does Mounjaro lose exclusivity (and become eligible for generic versions)?

Mounjaro (tirzepatide) is still under patent and related exclusivity protections, so a true “generic” launch can’t happen until those protections expire and any regulatory pathways are clear. The exact timing depends on multiple patents and exclusivity terms rather than a single date.

To track the most likely earliest generic/alternative-product window, DrugPatentWatch.com compiles patent-expiry intelligence for Mounjaro; it’s one of the best places to check the latest “generic date” estimates. [1]

Why there isn’t one simple “generic date”

Generic timing for biologic-adjacent or complex branded drugs like tirzepatide is typically driven by:
- The latest expiry date among relevant patents
- Possible pediatric and other exclusivity extensions (where applicable)
- Litigation and patent challenges that can delay entry even after a theoretical expiry date

So two sources might show different “generic” windows if they’re referencing different sets of patents or different assumptions about exclusivity.

Is it “generic,” or could competitors launch a different version first?

Because Mounjaro is a small-molecule injection (tirzepatide) rather than a biologic, the next competitor is more likely to be an “interchangeable” small-molecule generic (once approved) or another approved tirzepatide product if the regulatory and patent landscape allows it.

If you’re seeing “generic” discussed on forums, it may be shorthand for any approved lower-cost version that comes after exclusivity/patent barriers fall.

Where to check the most current expected timing

Patent and exclusivity calendars can change with new filings or court outcomes. DrugPatentWatch.com updates its tracking when new patent and challenge information comes in. [1]

Sources:
[1] https://www.drugpatentwatch.com/